Source: exhibitionnews.uk

Record international attendance at Informa’s CPHI & PMEC China 2025

What the source says

“Strong evidence that Sino-international trade is accelerating, was the recently completed 2025 edition of CPHI & PMEC China, which ran 24–26 June, in Shanghai New International Expo Center. Organisers Informa Markets reported a record 15,000 overseas visitors to the show – a 30% year-on-year increase.”

Background & context

The recent CPHI & PMEC China 2025 showcased the robust growth and global significance of China’s biopharmaceutical industry. The event highlighted a record attendance of 109,056 participants from 147 countries, reinforcing China’s role as a pivotal player in the global biotech arena. Marked by a 30% increase in overseas visitors compared to the previous year, the event is testimony to the accelerating Sino-international trade dynamics.

What’s new

This year at CPHI & PMEC China, Informa Markets reported a remarkable influx of overseas visitors, with 15,000 international attendees, symbolizing a renewed interest and opportunity in cross-border trade. The event also introduced expanded product zones, specifically tailored to accommodate the growing sectors of bioengineering and life sciences, which drew significant international participation.

Why it matters for exhibitors

For exhibitors, CPHI & PMEC China represents an unparalleled platform for accessing a diverse and expansive market. With China accounting for a third of big pharma’s in-licensed assets and being the largest single market for active pharmaceutical ingredient production, the exhibition serves as a critical juncture for establishing partnerships, showcasing innovations, and navigating the complexities of regulatory cooperation.

Opportunities for contractors

Contractors can find promising opportunities through:

• Expanding their offerings in the newly emphasized product zones.
• Engaging with international attendees looking for partnerships with Chinese firms.
• Leveraging the high concentration of industry leaders gathered at the event.
• Participating in the events and conferences to enhance their visibility and credibility.

Market outlook & action checklist

• Evaluate participation in CPHI & PMEC Shenzhen (1-3 September 2025) for further exposure.
• Monitor trends in bioengineering and life sciences to align services offered.
• Build relationships with international pharma companies looking for collaborations.
• Prepare marketing materials targeting the evolving needs of the biotech industry.

Executive Summary

• Record attendance of 109,056 participants at CPHI & PMEC China 2025.
• 30% increase in overseas visitors indicating strong international interest.
• Expanded focus on bioengineering and life sciences product zones.
• China accounts for one-third of big pharma’s in-licensed assets.

Attribution: Original article. This post provides original commentary/analysis and brief facts for discovery and fair use. All rights remain with the original publisher.